These therapeutic agents block immune-inhibitory receptors, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein (PD-1) on activated T cells to promote host immunity against tumor cells and improve T cell functionality [1,2]. Here, CTLA4 is linked to neoplasm.